share_log

The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare Conference

The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare Conference

腫瘤學研究所將參加瑞士信貸第31屆年度醫療會議
GlobeNewswire ·  2022/11/01 08:06

CERRITOS, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, and its Chief Financial Officer, Mihir Shah, will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes on Thursday, November 10.

全球通訊社加利福尼亞州塞裏託斯2022年11月1日電美國最大的基於價值的腫瘤學組織之一腫瘤研究所公司(納斯達克:TOI)今天宣佈,其首席執行官布拉德·海弗利和首席財務官米希爾·沙阿將參加11月10日(星期四)在帕洛斯維爾德斯舉行的瑞士信貸第31屆年度醫療大會。

About The Oncology Institute, Inc.

腫瘤學研究所簡介

Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .

TOI成立於2007年,通過在社區環境中提供高度專業化的、基於價值的癌症護理來推動腫瘤學的發展。TOI為大約170萬患者提供基於證據的尖端癌症護理,包括臨牀試驗、輸血和其他傳統上與最先進的護理提供機構相關的護理提供模式。TOI擁有90多名受僱的臨牀醫生和50多個診所的700多名隊友,而且還在不斷增長,TOI正在讓腫瘤學變得更好。有關更多信息,請訪問。

Contacts

聯繫人

Media

媒體

The Oncology Institute
Julie Korinke
juliekorinke@theoncologyinstitute.com(562) 735-3226 x 88806

腫瘤學研究所
朱莉·科林克
電子郵件:juliekorinke@theoncologyInstitute te.com

Juan Lezama
juanlezama@theoncologyinstitute.com(562) 374-8434

胡安·萊扎馬
郵箱:juanlezama@theoncologyInstitute te.com(562)374-8434

Investors

投資者

Solebury Trout
Maria Lycouris
investors@theoncologyinstitute.com

索爾伯裏鮭魚
瑪麗亞·呂庫利斯
郵箱:Investors@theoncologyInstitute te.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論